GREATER SPECIFICITY, GREATER CERTAINTY

Confirm Rx[™] ICM with SharpSense[™] Technology uses additional discriminators to confirm or reject detections made by existing Confirm Rx[™] ICM algorithms—significantly improving the accuracy of Atrial Fibrillation (AF), Bradycardia and Pause detected episodes.

97%

DETECTION*

More discerning—better sensing.

SharpSense™ Technology harnesse
the power of extra discriminators
to improve accuracy. False
detection of potential events is
now reduced by 97%.¹

8× O

FIRM

By maintaining a high relative sensitivity and improving the Positive Predictive Value (PPV), Confirm Rx^{T} ICM with SharpSense Technology monitors and stores true arrhythmic events.

Greater specificity means greater certainty—allowing you to decide clearly and confidently on a diagnosis, and enabling more patients to live fuller lives.



ENHANCEMENT GOALS

1 Maintain base algorithm high sensitivity 2 Improve specificity of device performance

HOW SHARPSENSE™ TECHNOLOGY DISCERNS

ARRHYTHMIA	SHARPSENSE™ TECHNOLOGY
ATRIAL FIBRILLATION (AF)	 Base AF algorithm is published in DETECT AF to have 100% patient sensitivity SharpSense™ Technology builds on base AF algorithm to improve specificity with minimal impact on sensitivity Analyzes 30 seconds of pre-trigger rhythm Calculates ensemble average to detect P-waves
BRADYCARDIA	 Calculates customized secondary threshold based on beats in 4 windows Considers R-wave variability and accounts for P-wave, R-wave and T-wave characteristics
PAUSE UNDERSENSING	 Calculates customized threshold based on beats in 6-second pre-trigger window (from last sensed beat) Considers R-wave variability and accounts for P-wave and R-wave characteristics
PAUSE LOSS OF CONTACT (LOC)	Evaluates 2-second pre-trigger window for presence of signature noise pattern

- 1. Evaluation of Clinic Impact of Confirm Rx 1.2 Algorithm Enhancements. Abbott Document 60098828. April 2019.
- Design Validation Report and Trace Matrix, Insertable Cardiac Monitor (ICM) System. Abbott Documen Rev. F. March 2019

Rev. E. March 2019.

Abbott Dro Ct. Judo Modical Dr. Ct. Davil MN 55117 LICA Tol. 1 651 756 200

RX ONI

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications

Indications: The Confirm Rx[™] ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who a susceptible to developing atrial fibrillation. The Confirm Rx[™] ICM has not been specifically tested for pediatric use.

Contraindications: There are no known contraindications for the insertion of the Confirm Rx ICM. However, the patient

Adverse Events: Possible adverse events (in alphabetical order) associated with the device, include the following: Allergic react Bleeding, Chronic nerve damage, Erosion, Excessive fibrotic tissue growth, Extrusion, Formation of hematomas or cysts, Infecti Keloid formation and Migration. Refer to the User's Manual for detailed indications, contraindications, warnings, precautions at potential adverse events.

Additional information: Clinicians must log onto Merlin.net" Patient Care Network to view transmissions from patients' Confirm Rx" ICM. On Merlin.net "PCN they can configure transmission schedules and enable or disable features on a patient myMerlin" for Confirm Rx" ICM mobile app. Review of transmissions is dependent on the clinician and may not happen immediately following delivery of such transmissions.

Limitations: Patients may use their own Apple¹ or Android¹ mobile device to transmit information from their Confirm Rx⁻ICM using the myMerlin⁻ for Confirm Rx⁻ICM mobile app. To do so the device must be powered on, app must be installed, Bluetooth¹ wireless technology enabled and data coverage (cellular or WiFi¹) available. The myMerlin⁻ for Confirm Rx⁻ICM mobile app provides periodic patient monitoring based on clinician configured settings. Data is resent if the transmission was not sent successfully. However, there are many internal and external factors that can hinder, delay, or prevent acquisition and delivery of ICM and patient information as intended by the clinician. These factors include: patient environment, data services, mobile device operating system and settings. ICM memory capacity, clinic environment, schedule/configuration changes, or data processing.

An Abbott mobile transmitter is available for patients without their own compatible mobile device

™ Indicates a trademark of the Abbott group of companies.
‡ Indicates a third-party trademark, which is property of its respective owner.
Bluetooth and the Bluetooth logo are registered trademarks of Bluetooth SIG, It
© 2019 Abbott. All Rights Reserved.



CONFIRM Rx[™] ICM

with SharpSense[™] Technology

CAPTURING
THE RHYTHM
OF LIFE



ACCURATELY DISCERN AF

RELATIVE SENSITIVITY FOR AF²

ensemble average

Before logging an AF event, SharpSense[™] Technology analyzes the previous 30 seconds for the presence or absence of P-wave characteristics.

R-WAVE P-WAVE

CORRECTLY CAPTURE

BRADYCARDIA

SharpSense[™] Technology confirms Bradycardia episodes by dynamically increasing sensitivity between Bradycardia beats and applying a secondary threshold based on P-wave, R-wave and T-wave characteristics.

RELATIVE SENSITIVITY
FOR BRADYCARDIA²


P-WAVE

evaluation beat


PRECISELY DETECT PAUSE

RELATIVE SENSITIVITY
FOR PAUSE²

To accurately identify Pause episodes, SharpSense[™] Technology dynamically increases sensitivity by applying a secondary threshold, based on P-wave and R-wave characteristics, and evaluating evidence of loss of tissue contact.



AF DETECTION



REGULARITY: Regular or irregular rhythm pattern **VARIANCE:** Variance of R-R intervals **SUDDEN ONSET:** How the rhythm initiates

If an AF episode occurs, SharpSense $^{\mathsf{T}}$ Technology will check for P-waves by:

Scanning 30 seconds prior to initial AF trigger to determine qualified beats


- SharpSense™ Technology identifies beats that are within a range of pace (40–100 bpm)—Beat Selection
- SharpSense™ Technology layers the selected beats on top of each other to look for consistent P-wave morphology and significance of P-wave amplitude— Ensemble Average

____Vei

Verifies the absence of P-waves

- Stores AF episode if P-waves are not detected
- Rejects AF episode if P-waves are detected

BRADYCARDIA DETECTION



After Bradycardia is indicated, SharpSense™ Technology confirms an event by:

Opening 4 pre-trigger EGM windows


- One prior to each of the 4 Bradycardia beats detected
- Each window extends to the prior sensed beat
- Calculates customized secondary threshold based on P-wave, R-wave and T-wave characteristics

Applying a secondary threshold to each window

Determining the presence of undersensed beats

- Stores Bradycardia event if 3 of 4 detected beats meet Bradycardia criteria
- Rejects episode if 2 of 4 detected beats do not meet Bradycardia criteria

PAUSE DETECTION



After a Pause detection is triggered, SharpSense™ Technology evaluates and confirms a Pause event by:

Analyzing 6 seconds of EGM data prior to the last sensed beat

 Calculates customized secondary threshold based on P-wave and R-wave characteristics

Applying a secondary threshold to Pause window

Determining the presence of undersensed beats

Checking for loss of contact

- If no undersensed beats are identified, SharpSense™ Technology searches for the presence of signature oscillation
- Stores Pause episode if no signature oscillation is found
- Rejects Pause episode if oscillation is found